Market Intelligence, Clinical Progress, and High-Purity Reagents for B-Cell Malignancy and Autoimmune Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CD19 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CD19 ECD-Fc Fusion Protein / Mutant Protein. High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). Covers full ectodomain (Pro20-Lys291). | View CD19 Products |
| Gene Delivery | CD19 Promise-ORF / Lentivirus Premade Particles. Full-length ORF for stable CD19+ cell line construction. Ideal for CAR-T target validation. | View CD19 Products |
| Benchmark Ab | Anti-CD19 Recombinant (Sequence of FMC63 / Tafasitamab). Positive control for binding/blocking assays and Fc effector function. | View CD19 Products |
| Validator | CD19 siRNA Set. For knockdown verification and specificity controls in binding assays. | View CD19 Products |
| Related Target: CD20 | CD20 (MS4A1). Synergistic B-cell target for combination therapy to prevent antigen escape. | View CD20 Products |
| Related Target: CD22 | CD22 (SIGLEC2). Alternative B-cell antigen for resistant/relapsed patient populations; dual-targeting strategies. | View CD22 Products |
| Related Target: CD3E | CD3E. T-cell engagement component for CD19xCD3 bispecific validation. | View CD3E Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species cyno/mouse evaluation | Human/Mouse/Cyno CD19 ortholog proteins available with >95% purity; Sequence identity verified by Mass Spec. |
| Epitope-specific internalization (ADC development) | High-purity ECD-Fc preserves native Ig-like domain conformation; Suitable for SPR/BLI kinetics and pH-dependent release assays. |
| CAR-T specificity validation | Lentivirus-based stable cell lines display native membrane topology; Critical for conformation-sensitive scFv binding. |
| Preserving native glycosylation for CAR-T binding | Strictly HEK293 expressed to ensure proper structural folding and receptor recognition. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included for assay standardization. |
| False Positives | Validated siRNA included for target specificity checks; endotoxin-controlled proteins (<1EU/ug). |
Live CD19 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CD19 therapeutics is intensifying, with major players shifting focus from first-generation autologous CAR-T to next-generation allogeneic platforms, in vivo CAR-T, and combination regimens. Approved therapies (Tisagenlecleucel [Kymriah], Axicabtagene ciloleucel [Yescarta], Lisocabtagene maraleucel [Breyanzi], and Loncastuximab tesirine [Zynlonta]) have established clinical utility in B-ALL, DLBCL, and MCL. The next wave of R&D targets antigen escape mechanisms through epitope-bispecific designs, CD19/CD20 dual targeting, and emerging applications in severe autoimmune diseases such as systemic lupus erythematosus (SLE). First-generation therapies face saturation in hematological malignancies; breakthroughs are expected in off-the-shelf cell therapies and antibody-drug conjugates (ADCs) with novel payloads.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| CAR-T Cell Therapy | Novartis (Kymriah), Gilead/Kite (Yescarta, Tecartus), BMS (Breyanzi) | B-ALL, DLBCL, MCL, SLE | Cell-based binding validation (need Lentivirus-stable CD19+ cell lines for scFv screening) |
| ADC | ADC Therapeutics/Pfizer (Zynlonta) | Relapsed/Refractory DLBCL | Internalization Assay (need high-purity ECD-Fc for pH-dependent kinetic studies) |
| Bispecific T-Cell Engager | Amgen (Blincyto), Roche, Regeneron | B-ALL, B-Cell Malignancies | Heterodimer Validation (need cross-reactive Abs and CD3E co-expression systems) |
| Naked mAb | MorphoSys/Incyte (Monjuvi) | DLBCL (R/R) | Affinity/Blocking Assay (need unmutated ECD-Fc for epitope binning) |
Strategic Considerations for Differentiation
To develop best-in-class CD19 therapeutics, researchers must fine-tune affinity (moderate for CAR-T to prevent exhaustion, high for ADC to ensure internalization), validate cross-species reactivity (cyno/mouse orthologs), control epitope specificity (avoid off-target binding to CD20/CD22), and use benchmark antibodies for assay standardization. TarMart provides a complete ecosystem—high-purity ECD-Fc, lentivirus for stable cell lines, validated siRNA, and biosimilar controls—to address every critical assay need.